Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marin Kollef

Pulmonary Disease Saint Louis, MO Medical Doctor

NPI 1326077165 CMS profile 150161

1 Barnes Jewish Hospital Plz, Dept Internal Medicine, Saint Louis, MO 63110

Open in the dashboard

General payments

$264,040

299 records reported · program years 2019–2025

Research payments

$3,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marin Kollef of Saint Louis, MO is reported in the CMS Open Payments database as having received $264,040 across 299 general payments and $3,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,900 5
2024 General $2,373 2
2023 General $17,466 15
2022 General $19,000 8
2021 General $12,668 7
2021 Research $3,200 1
2020 General $32,585 25
2019 General $170,049 237

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marin Kollef
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Marin Kollef were reported at $9,900. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Marin Kollef Pulmonary Disease median Middle half National median
2019 $170,049 $377 $109–$1,340 $163
2020 $32,585 $230 $56–$907 $114
2021 $12,668 $269 $68–$1,072 $132
2022 $19,000 $390 $100–$1,457 $149
2023 $17,466 $419 $114–$1,659 $160
2024 $2,373 $476 $123–$1,818 $164
2025 $9,900 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $124,753 150 payments
  2. Shionogi Inc $57,146 35 payments
  3. Allergan Inc. $48,967 91 payments
  4. Tetraphase Pharmaceuticals, Inc. $11,866 8 payments
  5. Pfizer Inc. $8,793 7 payments
  6. Sage Therapeutics, Inc. $3,600 1 payment
  7. La Jolla Pharmaceutical Company $2,815 1 payment
  8. AcelRx Pharmaceuticals, Inc. $2,250 1 payment
  9. GlaxoSmithKline, LLC. $1,557 1 payment
  10. Cidara Therapeutics, Inc. $1,225 1 payment
  11. Other $1,068 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $114,225 41 payments
  2. Consulting Fee $83,062 36 payments
  3. Travel and Lodging $50,149 154 payments
  4. Honoraria $12,226 5 payments
  5. Food and Beverage $4,368 61 payments
  6. Gift $9 2 payments
Products named General payments · program years 2019–2025
  1. ZERBAXA $65,674 106 payments
  2. Fetroja $44,657 23 payments
  3. AVYCAZ $42,703 84 payments
  4. Xerava $11,866 8 payments
  5. TEFLARO $6,264 7 payments
  6. GIAPREZA $2,815 1 payment
  7. DSUVIA $2,250 1 payment
  8. REZZAYO $1,225 1 payment
  9. ACCELERATE PHENOTEST BC KIT $78 1 payment
  10. BIOFIRE RESPIRATORY PANEL 2.1 $40 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $3,200 1 payment

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$48,625

Medicare's payments for the services billed

Medicare patients

159

Average age 66

Services billed

472

77 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 64%
Diabetes 58%
Heart failure 57%
Ischemic heart disease 54%
Arthritis 49%
COPD 48%
Atrial fibrillation 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fetroja
  • Shionogi Inc $2,373
$2,373 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record